
114870-03-0
- Product Name:Fondaparinux sodium
- Molecular Formula:C31H43N3Na10O49S8
- Purity:99%
- Molecular Weight:1728.1
Product Details;
CasNo: 114870-03-0
Molecular Formula: C31H43N3Na10O49S8
Top Quality Fondaparinux sodium 114870-03-0 Hot Sell In Stock We supply high quality Fondaparinux sodium (CAS 114870-03-0), in stock, factory directly supply to clients, lower prices, more competitiveness.
What is the Fondaparinux sodium ?
Fondaparinux sodium is , while it's Molecular Formula is C31H43N3O49S8*10Na. Synthetic pentasaccharide corresponding to the anti-thrombin binding site of heparin. Anti-thrombotic.
What is the CAS number for Fondaparinux sodium ?
The CAS number of Fondaparinux sodium is 114870-03-0.
More information of Fondaparinux sodium 114870-03-0 are:
Synonyms |
a-D-Glucopyranoside, methylO-2-deoxy-6-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(1?;4)-O-b-D-glucopyranuronosyl-(1?;4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(1?;4)-O-2-O-sulfo-a-L-idopyranuronosyl-(1?;4)-2-deoxy-2-(sulfoamino)-,6-(hydrogen sulfate), decasodium salt (9CI);Arixtra;IC 85158;IC 851589;Org 31540;SR 90107A;Xantidar; |
CAS Number |
114870-03-0 |
Molecular Formula |
C31H43N3O49S8*10Na |
Molecular Weight |
1728.1 |
HS CODE |
3822000002 |
PSA |
900.82000 |
LogP |
-9.34120 |
What is Fondaparinux sodium (114870-03-0) used for?
Fondaparinux sodium was first introduced in the US for prophylaxis of deep vein thrombosis which may lead to pulmonary embolism following major orthopaedic surgery. Fondaparinux is the first of a new class of antithrombic agents distinct from low molecular weight heparin (LMWH) and heparin. This entirely synthetic molecule is a copy of the heparin pentasaccharide sequence, the shortest fragment able to catalyze antithrombin lllmediated inhibition of factor Xa thereby inhibiting thrombin generation without antithrombin action. Fondaparinux does not display significant effects on coagulation tests (such as activated partial thromboplastin time and prothrombin time), does not bind to platelet factor 4 or promote heparin-induced thrombocytopenia. In phase III studies, fondaparinux significantly reduced the incidence of thromboembolism following orthopedic surgery, with an overall risk reduction of 50% in comparison to the LMWH, enoxaparin. Following subcutaneous administration, fondaparinux has a nearly complete bioavailability, a rapid onset of action, a prolonged half-life (17.2 h) enabling once daily dosing and is not metabolized preceeding renal excretion. The drug appears to be generally safe, with haemoragic complications either comparable to or higher than those for LMWH.
Articles related to Fondaparinux sodium:
Article |
Source |
Synthesis of methyl glycoside derivatives of tri- and penta-saccharides related to the antithrombin III-binding sequence of heparin, employing cellobiose as a key starting-material. |
Ichikawa,Monden,Kuzuhara , p. 37 - 64 (2007/10/02) |
How to get the best price on Fondaparinux sodium?
Hangzhou Shanyi Biotechnology Co., Ltd. is a quality supplier and manufacturer of Fondaparinux sodium . You can buy high quality, low price Fondaparinux sodium 114870-03-0 here. Contact us.
Relevant Products
-
Sodium 4-aminosalicylate
CAS:133-10-8
-
4-Aminosalicylic acid
CAS:65-49-6